Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER vs KAON CL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse transmission, muscle contraction, and cardiac function. Dextrose provides a source of calories and may enhance cellular potassium uptake via insulin-mediated shift.
Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.
Correction of hypokalemia,Prevention of hypokalemia in patients receiving potassium-depleting therapies,Intravenous source of calories (dextrose component)
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving digitalis and diuretics,Off-label: prevention of hypokalemia in patients on potassium-wasting diuretics
Intravenous infusion; typical adult dose: 10-20 m Eq per hour, not exceeding 40 m Eq per dose and 200 m Eq per day, titrated based on serum potassium and ECG monitoring.
Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).
The terminal elimination half-life of potassium is approximately 1-1.5 hours in individuals with normal renal function. This reflects rapid redistribution and renal clearance. In anephric or oliguric patients, half-life is prolonged significantly, leading to accumulation and risk of hyperkalemia. Dextrose has a half-life of 15-20 minutes due to rapid cellular uptake and metabolism.
Terminal half-life is approximately 0.5–1.5 hours in healthy individuals; prolonged in renal impairment (up to 6–12 hours in end-stage renal disease).
Potassium is primarily excreted unchanged by the kidneys; dextrose is metabolized to CO2 and water via glycolysis and the Krebs cycle.
Not significantly metabolized; primarily excreted unchanged by the kidneys, with minor fecal elimination.
Renal excretion accounts for approximately 90% of potassium elimination, primarily via distal tubular secretion and reabsorption. Fecal excretion is minimal (<10%). The dextrose component is completely metabolized to CO2 and water, with no direct renal excretion.
Primarily renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
Potassium is not significantly protein-bound (<10%). Dextrose has negligible protein binding. No specific binding proteins identified for potassium; it exists as free ion in plasma.
Minimal protein binding (<1%); not significantly bound to plasma proteins.
Potassium Vd is approximately 0.5-0.6 L/kg, indicating distribution primarily into extracellular fluid. Total body potassium is ~50 m Eq/kg, with 98% intracellular. The clinical meaning: initial dose distributes into ECF before equilibrating with ICF; rapid IV administration can cause transient hyperkalemia.
Approximately 0.5–0.8 L/kg; distributes mainly in extracellular fluid, with minimal intracellular penetration.
Intravenous administration yields 100% bioavailability. Oral potassium chloride has ~90-100% bioavailability, but this formulation is not for oral use. Dextrose only given IV; not applicable for oral.
Oral bioavailability is ~90-100% due to complete absorption of potassium chloride; food may slightly reduce absorption but overall high.
For GFR 30-50 m L/min: reduce infusion rate by 25%; GFR 15-29: reduce rate by 50%; GFR <15: avoid use or use with extreme caution at reduced rate, monitor potassium closely.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: use with caution, reduce dose and monitor serum potassium; GFR < 10 m L/min: contraindicated due to risk of hyperkalemia.
No specific Child-Pugh based adjustments; monitor serum potassium and acid-base status closely in hepatic impairment due to risk of hyperkalemia.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of hyperkalemia from potential electrolyte disturbances.
Intravenous infusion; 0.5-1 m Eq/kg per dose, maximum 40 m Eq per dose, infused at rate not exceeding 0.5-1 m Eq/kg/hour; adjust based on serum potassium and clinical response.
Dose determined by physician based on serum potassium levels and underlying condition; typical oral dose: 1-3 m Eq/kg/day in divided doses, not to exceed 1 m Eq/kg per single dose or maximum 4 m Eq/kg/day. Extended-release tablets not recommended for children < 12 years unless specifically directed.
Use lower initial infusion rates (e.g., 5-10 m Eq/hour) due to age-related decline in renal function; monitor serum potassium and renal function frequently; avoid rapid infusion.
Elderly patients often have reduced renal function and may require lower starting doses (e.g., 20 m Eq twice daily) with close monitoring of serum potassium and renal function. Avoid if e GFR < 30 m L/min/1.73 m².
Potassium chloride injection concentrate must be diluted before use to avoid fatal hyperkalemia. Accidental administration of undiluted concentrate can lead to cardiac arrest.
Potassium chloride can cause hyperkalemia and cardiac arrest if administered too rapidly or in excessive doses. Avoid use in patients with severe renal impairment or conditions that predispose to hyperkalemia.
Risk of hyperkalemia, especially in patients with renal impairment,Cardiac monitoring recommended during infusion,Avoid rapid intravenous administration,Use with caution in patients with cardiac disease, adrenal insufficiency, or acid-base disorders,May cause phlebitis at injection site
Hyperkalemia risk, especially in renal impairment,Avoid solid oral forms in patients with esophageal stricture or delayed GI transit,May exacerbate metabolic alkalosis,Monitor serum potassium levels regularly
Hyperkalemia (serum potassium >5.5 m Eq/L),Severe renal failure with oliguria or azotemia,Concurrent use of potassium-sparing diuretics (unless under close monitoring),Acidosis (may worsen hyperkalemia),Crush injury or massive hemolysis (risk of acute hyperkalemia),Addison's disease (untreated)
Hyperkalemia,Severe renal impairment (oliguria, anuria, or azotemia),Concurrent use of potassium-sparing diuretics or ACE inhibitors (with caution),Untreated Addison's disease,Acute dehydration or heat cramps
No specific food interactions with IV potassium chloride and dextrose. However, while on treatment, avoid high-potassium foods (e.g., bananas, oranges, potatoes) unless directed by your doctor, as concurrent dietary potassium may increase risk of hyperkalemia.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium, as they may increase risk of hyperkalemia. Taking with food reduces gastrointestinal irritation.
No evidence of teratogenicity from potassium chloride or dextrose at standard concentrations. Potassium chloride is a normal constituent of body fluids; dextrose is a nutrient. No increased risk of congenital anomalies reported. However, maternal hyperkalemia or severe hypoglycemia may indirectly affect fetal well-being.
Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.
Potassium chloride and dextrose are normal constituents of breast milk. Supplementation does not significantly alter milk composition. No adverse effects in nursing infants expected. M/P ratio not applicable as substances are endogenous.
Potassium is a normal component of breast milk. Exogenous potassium does not significantly alter milk levels. M/P ratio not established; considered compatible with breastfeeding.
No specific dose adjustments required due to pregnancy. Monitor for fluid overload in preeclampsia or compromised cardiac function. Glucose-containing solutions necessitate glucose monitoring in diabetes. Potassium supplementation should be guided by serum potassium levels.
No dose adjustment required for potassium chloride in pregnancy; pharmacokinetics are substantially unchanged.
Potassium chloride 0.3% in dextrose 5% provides 40 m Eq/L of potassium and 50 g/L of dextrose. Administer via peripheral line; central line preferred for concentrations >40 m Eq/L. Never give IV push. Infusion rate should not exceed 10 m Eq/h or 200 m Eq/24h without cardiac monitoring. Contraindicated in severe hyperkalemia, renal failure with oliguria, and untreated Addison's disease. Use with caution in patients with cardiac disease, digoxin therapy, or metabolic acidosis. Monitor serum potassium and ECG continuously during infusion.
KAON CL is a potassium chloride supplement. Monitor serum potassium levels frequently, especially in patients with renal impairment or those on ACE inhibitors/ARBs, NSAIDs, or potassium-sparing diuretics to avoid hyperkalemia. Administer with food to minimize gastrointestinal irritation. Do not crush or chew extended-release formulations; swallow whole. Hypomagnesemia can cause refractory hypokalemia; check magnesium levels if potassium repletion fails.
This medication is given through a vein to correct low potassium levels.,Report any pain, redness, or swelling at the IV site immediately.,You may experience increased thirst or urination due to the dextrose content.,Do not stop treatment abruptly without consulting your healthcare provider.,Inform your doctor of all medications you take, especially digoxin and diuretics.
Take this medication with a full glass of water and with food to reduce stomach upset.,Do not crush, chew, or break extended-release tablets; swallow them whole.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms of high potassium such as muscle weakness, irregular heartbeat, numbness/tingling, or confusion.,Keep all appointments for blood tests to monitor kidney function and potassium levels.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER vs KAON CL, answered by our medical review team.
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse transmission, muscle contraction, and cardiac function. Dextrose provides a source of calories and may enhance cellular potassium uptake via insulin-mediated shift.. KAON CL is a Electrolyte Supplement (Potassium) that works by Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER and KAON CL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose: 10-20 m Eq per hour, not exceeding 40 m Eq per dose and 200 m Eq per day, titrated based on serum potassium and ECG monitoring.. The standard adult dose of KAON CL is: Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER and KAON CL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity from potassium chloride or dextrose at standard concentrations. Potassium chloride is a normal constituent of body fluids; dextrose is a nutrient. No . KAON CL is classified as Category C. Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.